Department of Health
and Human Services (HHS)
and Human Services (HHS)
December 15, 2020
PA-20-265 - PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
PA-20-261 - PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
PA-20-260 - PHS 2020 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
PA-20-262 - PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
Office of The Director, National Institutes of Health (OD)
The purpose of this notice is to update information regarding the total funding support normally allowed for Phase I and Phase II Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications.
Section II. Award Information
Currently Reads:
Award Budget
Total funding support (direct costs, indirect costs, fee) normally may not exceed $256,580 for Phase I awards and $1,710,531 for Phase II awards. For specific topics, NIH may exceed these total award amounts. The current list of approved topics can be found athttps://sbir.nih.gov/funding#omni-sbir or in Appendix A of PHS 2020-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA.
Each participating component may also set their own budget limit (higher or lower than the above) in the “Limited Amount of Award Section” of their respective topics section. Applicants are strongly encouraged to contact program officials prior to submitting any application in excess of the total award amounts listed above and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
Phase IIB budgets must be submitted in accordance with participating IC-specific budget limitations described in the current PHS 2020-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA.
Revised to Read (changes shown in italics):
Award Budget
Total funding support (direct costs, indirect costs, fee) normally may not exceed $259,613 for Phase I awards and $1,730,751 for Phase II awards. For specific topics, NIH may exceed these total award amounts. The current list of approved topics can be found athttps://sbir.nih.gov/funding#omni-sbir or in Appendix A of PHS 2020-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA.
Each participating component may also set their own budget limit (higher or lower than the above) in the “Limited Amount of Award Section” of their respective topics section. Applicants are strongly encouraged to contact program officials prior to submitting any application in excess of the total award amounts listed above and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
Phase IIB budgets must be submitted in accordance with participating IC-specific budget limitations described in the current PHS 2020-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA.
All other aspects of this FOA remain the same.
Stephanie Fertig, MBA| HHS Small Business Program Lead
SEED (Small business Education and Entrepreneurial Development)
Office of Extramural Research